TABLE OF CONTENTS I
LIST OF CHARTS XXXI

XEXECUTIVE SUMMARY 1

MARKET OVERVIEW 1

COMPETITIVE LANDSCAPE 3

MARKET TRENDS 5

KEY MARKET DEVELOPMENTS 6

MARKETS INCLUDED 12

VERSION HISTORY 13

IDATA PHARMA'S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 17
Step 3: Preparation for Interviews & Questionnaire Design 19
Step 4: Performing Primary Research 20
Step 5: Research Analysis: Establishing Baseline Estimates 22
Step 6: Market Forecasts and Analysis 24
Step 7: Identify Strategic Opportunities 26
Step 8: Final Review and Market Release 27
Step 9: Customer Feedback and Market Monitoring 28

MECHANISM OF ACTION 29
2.1 INTRODUCTION 29
2.1.1 Tumor Necrosis Factor (TNF) 32
2.1.2 B-cell Inhibitors 32
2.1.3 Interleukin Inhibitors 32
2.1.4 Janus Kinase Inhibitors 32
2.1.5 Co-stimulation Modulators 33

PRODUCT ASSESSMENT 34
3.1 KEY MARKETED PRODUCTS 34
3.1.1 Abatacept (ORENCIA®) 34
3.1.1.1 Future Developments 34
3.1.1.2 Currently Marketed Products by Company 36
3.1.2 Adalimumab (HUMIRA®) 37
3.1.2.1 Future Developments 38
3.1.2.2 Currently Marketed Products by Company 40
3.1.3 Certolizumab pegol (CIMZIA®) 41
3.1.3.1 Future Developments 41
3.1.3.2 Currently Marketed Products by Company 42
3.1.4 Etanercept (ENBREL®, Benepali®) 43
3.1.4.1 Future Developments 44
3.1.4.2 Currently Marketed Products by company 46
3.1.5 Golimumab (SIMPONI®) 47
3.1.5.1 Future Developments 47
3.1.5.2 Currently Marketed Products by company 48
3.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®) 49
3.1.6.1 Future Developments 50
3.1.6.2 Currently Marketed Products by company 51
3.1.7 Natalizumab (TYSABRI®) 52
3.1.7.1 Currently Marketed Products by company 53
3.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™) 54
3.1.8.1 Future Developments 54
3.1.8.2 Currently Marketed Products by company 56
3.1.9 Tocilizumab (Actemra®/RoActemra®) 57
3.1.9.1 Currently Marketed Products by company 58
3.1.10 Tofacitinib (XELJANZ®) 59
3.1.10.1 Future Developments 59
3.1.10.2 Currently Marketed Products by company 61
3.1.11 Ustekinumab (STELARA®) 62
3.1.11.1 Future Developments 62
3.1.11.2 Currently Marketed Products by company 63
3.1.12 Vedolizumab (ENTYVIO®) 64
3.1.12.1 Currently Marketed Products by company 65
3.2 KEY PRODUCTS IN PIPELINE 66
3.2.1 Barcitinb (Olumiant®) 66
3.2.2 Guselkumab (Tremfya™) 66
3.2.3 Cobitolimod (Kappaproct®) 66
3.2.4 Mavrilimumab 67
3.2.5 Sirukumab 67
3.2.6 Vobarilizumab 68
3.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES 70
3.4 CLINICAL TRIAL BY DISEASE 75
3.4.1 Rheumatoid Arthritis 76
3.4.1.1 Study Completion Date: 2017 76
3.4.1.2 Study Completion Date: 2016 803.4.2 Crohn's Disease (CD) 95
3.4.2.1 Study Completion Date: 2017 95
3.4.2.2 Study Completion Date: 2016 96
3.4.2.3 Study Completion Date: 2015 98
3.4.3 Ankylosing Spondylitis (AS) 101
3.4.3.1 Study Completion Date: 2017 101
3.4.3.2 Study Completion Date: 2016 101
3.4.3.3 Study Completion Date: 2015 102
3.4.4 Psoriasis (Ps) 104
3.4.4.1 Study Completion Date: 2017 104
3.4.4.2 Study Completion Date: 2016 108
3.4.5 Ulcerative Colitis (UC) 118
3.4.5.1 Study Completion Date: 2016 118
3.4.5.2 Study Completion Date: 2015 122

UNITED STATES IMMUNOLOGY MARKET OVERVIEW 125
4.1 INTRODUCTION 125
4.2 MARKET OVERVIEW 126
4.3 MARKET SHARE ANALYSIS 131
4.4 DRIVERS AND LIMITERS 134
4.4.1 Market Drivers 134
4.4.2 Market Limiters 137
4.5 COMPETITIVE ANALYSIS 140

COUNTRY PROFILE 148
5.1 UNITED STATES 148
5.1.1 Population and Demographics 148
5.1.2 Prevalence of Immunology Diseases 148
5.1.3 Drug Cost Analysis 151
5.1.4 Annual Drug Cost Analysis 154
5.1.5 Disease Treatment Population Size 157
5.1.6 Units of Drugs Sold 159

RHEUMATOID ARTHRITIS MARKET 161
6.1 INTRODUCTION 161
6.1.1 Causes and Disease Progression 161
6.1.2 Diagnosis and Treatment Options 162
6.1.3 Symptoms and Complications 162
6.1.4 Epidemiology 163
6.2 MARKET OVERVIEW 164
6.3 MARKET SHARE ANALYSIS 168

CROHN'S DISEASE MARKET 170
7.1 INTRODUCTION 170
7.1.1 Causes and Disease Progression 170
7.1.2 Diagnosis and Treatment Options 171
7.1.3 Symptoms and Complications 172
7.1.4 Epidemiology 172
7.2 MARKET OVERVIEW 174
7.3 TREND ANALYSIS 178

ANKYLOSING SPONDYLITIS MARKET 180
8.1 INTRODUCTION 180
8.1.1 Causes and Disease Progression 180
8.1.2 Diagnosis and Treatment Options 181
8.1.3 Symptoms and Complications 181
8.1.4 Epidemiology 182
8.2 MARKET OVERVIEW 183
8.3 TREND ANALYSIS 187

PSORIASIS MARKET 189
9.1 INTRODUCTION 189
9.1.1 Causes and Disease Progression 189
9.1.2 Diagnosis and Treatment Options 190
9.1.3 Symptoms and Complications 191
9.1.4 Epidemiology 192
9.2 MARKET OVERVIEW 194
9.3 TREND ANALYSIS 198

ULCERATIVE COLITIS MARKET 200
10.1 INTRODUCTION 200
10.1.1 Causes and Disease Progression 200
10.1.2 Diagnosis and Treatment Options 201
10.1.3 Symptoms and Complications 201
10.1.4 Epidemiology 202
10.2 MARKET OVERVIEW 203
10.3 TREND ANALYSIS 207COMPANY PROFILES 209
11.1 ABBVIE INC. 209
11.1.1 Business Overview 209
11.1.2 Financials 211
11.1.3 SWOT Analysis 212
11.1.3.1 Strengths: 212
11.1.3.2 Weakness: 213
11.1.3.3 Opportunity: 213
11.1.3.4 Threats: 214
11.2 AMGEN INC. 216
11.2.1 Business Overview 216
11.2.2 Financials 217
11.2.3 SWOT Analysis 218
11.2.3.1 Strengths: 218
11.2.3.2 Weaknesses: 219
11.2.3.3 Opportunities: 220
11.2.3.4 Threats: 221
11.3 BIOGEN IDEC 223
11.3.1 Business Overview 223
11.3.2 Financials 224
11.3.3 SWOT Analysis 225
11.3.3.1 Strengths: 225
11.3.3.2 Weakness: 226
11.3.3.3 Opportunities: 226
11.3.3.4 Threats: 228
11.4 BRISTOL-MYERS SQUIBB 229
11.4.1 Business Overview 229
11.4.2 Financials 230
11.4.3 SWOT Analysis 232
11.4.3.1 Strengths: 232
11.4.3.2 Weakness: 233
11.4.3.3 Opportunities: 233
11.4.3.4 Threats: 235
11.5 HOFFMANN-LA ROCHE LTD 237
11.5.1 Business Overview 237
11.5.2 Financials 238
11.5.3 SWOT Analysis 239
11.5.3.1 Strengths: 239
11.5.3.2 Weakness: 240
11.5.3.3 Opportunities: 241
11.5.3.4 Threats: 241
11.6 JOHNSON & JOHNSON/JANSSEN 243
11.6.1 Business Overview 243
11.6.2 Financials 244
11.6.3 SWOT Analysis 245
11.6.3.1 STRENGTHS: 245
11.6.3.2 Weakness: 246
11.6.3.3 Opportunities: 247
11.6.3.4 Threats: 248
11.7 NOVARTIS AG 250
11.7.1 Business Overview 250
11.7.2 Financials 251
11.7.3 SWOT Analysis 252
11.7.3.1 STRENGTHS: 252
11.7.3.2 Weakness: 253
11.7.3.3 Opportunities: 253
11.7.3.4 Threats: 255
11.8 PFIZER INC. 256
11.8.1 Business Overview 256
11.8.2 Financials 257
11.8.3 SWOT Analysis 258
11.8.3.1 Strengths: 258
11.8.3.2 Weakness 259
11.8.3.3 Opportunities 260
11.8.3.4 Threats: 261
11.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 263
11.9.1 Business Overview 263
11.9.2 Financials 264
11.9.3 SWOT Analysis 265
11.9.3.1 Strengths: 265
11.9.3.2 Weakness: 266
11.9.3.3 Opportunities 266
11.9.3.4 Threats: 268
11.10 UCB S.A. 270
11.10.1 Business Overview 270
11.10.2 Financials 271
11.10.3 SWOT Analysis 272
11.10.3.1 Strengths: 272
11.10.3.2 Weakness: 273
11.10.3.3 Opportunities: 273
11.10.3.4 Threats: 274

ABBREVIATIONS 275

APPENDIX: COMPANY PRESS RELEASES 278-1024

Chart List
Chart 1 1: Immunology Market by Segment, U.S., 2013 - 2023 2
Chart 1 2: Immunology Market Overview, U.S., 2016 & 2023 2
Chart 4 1: Immunology Market by Segment, U.S., 2014 - 2024 129
Chart 4 2: Immunology Market Breakdown, U.S., 2017 130
Chart 4 3: Immunology Market Breakdown, U.S., 2024 130
Chart 4 7: Market Share Analysis, Immunology Market, U.S., 2014 - 2024 133
Chart 4 8: Leading Competitors, Immunology Market, U.S., 2017 142
Chart 6 1: Rheumatoid Arthritis Market by Segment, U.S., 2014 - 2024 156
Chart 6 2: Rheumatoid Arthritis Market Breakdown, U.S., 2017 157
Chart 6 3: Rheumatoid Arthritis Market Breakdown, U.S., 2024 157
Chart 6 4: Growth Rates by Segment, Rheumatoid Arthritis Market, U.S., 2014 - 2024 159
Chart 6 5: Leading Competitors, Rheumatoid Arthritis Market, U.S., 2017 161
Chart 7 1: Crohn's Disease Market by Segment, U.S., 2014 - 2024 168
Chart 7 2: Crohn's Disease Market Breakdown, U.S., 2017 169
Chart 7 3: Crohn's Disease Market Breakdown, U.S., 2024 169
Chart 7 4: Growth Rates by Segment, Crohn's Disease Market, U.S., 2014 - 2024 171
Chart 7 5: Leading Competitors, Crohn's Disease Market, U.S., 2017 173
Chart 8 1: Ankylosing Spondylitis Market by Segment, U.S., 2014 - 2024 179
Chart 8 2: Ankylosing Spondylitis Market Breakdown, U.S., 2017 180
Chart 8 3: Ankylosing Spondylitis Market Breakdown, U.S., 2024 180
Chart 8 4: Growth Rates by Segment, Ankylosing Spondylitis Market, U.S., 2014 - 2024 182
Chart 8 5: Leading Competitors, Ankylosing Spondylitis Market, U.S., 2017 184
Chart 9 1: Psoriasis Market by Segment, U.S., 2014 - 2024 192
Chart 9 2: Psoriasis Market Breakdown, U.S., 2017 193
Chart 9 3: Psoriasis Market Breakdown, U.S., 2024 193
Chart 9 4: Growth Rates by Segment, Psoriasis Market, U.S., 2014 - 2024 195
Chart 9 5: Leading Competitors, Psoriasis Market, U.S., 2017 197
Chart 10 1: Ulcerative Colitis Market by Segment, U.S., 2014 - 2024 203
Chart 10 2: Ulcerative Colitis Market Breakdown, U.S., 2017 204
Chart 10 3: Ulcerative Colitis Market Breakdown, U.S., 2024 204
Chart 10 4: Growth Rates by Segment, Ulcerative Colitis Market, U.S., 2014 - 2024 206
Chart 10 5: Leading Competitors, Ulcerative Colitis Market, U.S., 2017 208
Chart 11 1: Enbrel® Revenue, 2012-2016 219

Figure List
Figure 1 1: Immunology Market Share Ranking by Segment, U.S., 2017 3
Figure 1 2: Companies Researched in this Report, U.S., 2017 4
Figure 1 3: Factors Impacting the Immunology Market 5
Figure 1 4: Recent Events in the Immunology Market, Global, 2016 - 2017, AbbVie 6
Figure 1 5: Recent Events in the Immunology Market, Global, 2016 - 2017, Amgen 6
Figure 1 6: Recent Events in the Immunology Market, Global, 2016 - 2017, AstraZeneca 7
Figure 1 7: Recent Events in the Immunology Market, Global, 2016 - 2017, Biogen 7
Figure 1 8: Recent Events in the Immunology Market, Global, 2016 - 2017, BMS 7
Figure 1 9: Recent Events in the Immunology Market, Global, 2016 - 2017, Eli Lilly 8
Figure 1 10: Recent Events in the Immunology Market, Global, 2016 - 2017, Roche 8
Figure 1 11: Recent Events in the Immunology Market, Global, 2016 - 2017, Janssen 9
Figure 1 12: Recent Events in the Immunology Market, Global, 2016 - 2017, Merck 9
Figure 1 13: Recent Events in the Immunology Market, Global, 2016 - 2017, Merck 10
Figure 1 14: Recent Events in the Immunology Market, Global, 2016 - 2017, Pfizer 11
Figure 1 15: Recent Events in the Immunology Market, Global, 2016 - 2017, Takeda 11
Figure 1 16: Recent Events in the Immunology Market, Global, 2016 - 2017, UCB 11
Figure 1 17: Immunology Markets Covered, U.S., 2016 (1 of 2) 12
Figure 1 18: Immunology Markets Covered, U.S., 2016 (2 of 2) 13
Figure 1 19: Version History 13
Figure 2 1: Classification by Mechanism of Action 31
Figure 3 1: Marketed Product Portfolio by Company 36
Figure 3 2: Marketed Product Portfolio by Company 40
Figure 3 3: Marketed Product Portfolio by Company 42
Figure 3 4: Marketed Product Portfolio by Company 46
Figure 3 5: Marketed Product Portfolio by Company 48
Figure 3 6: Marketed Product Portfolio by Company 51
Figure 3 7: Marketed Product Portfolio by Company 53
Figure 3 8: Marketed Product Portfolio by Company 56
Figure 3 9: Marketed Product Portfolio by Company 58
Figure 3 10: Marketed Product Portfolio by Company 61
Figure 3 11: Marketed Product Portfolio by Company 63
Figure 3 12: Marketed Product Portfolio by Company 65
Figure 3 13: Other products in pipeline 69
Figure 3 14: Pipeline Product Portfolio by Company (1 of 5) 70
Figure 3 15: Pipeline Product Portfolio by Company (2 of 5) 71
Figure 3 16: Pipeline Product Portfolio by Company (3 of 5) 72
Figure 3 17: Pipeline Product Portfolio by Company (4 of 5) 73
Figure 3 18: Pipeline Product Portfolio by Company (5 of 5) 74
Figure 3 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA) 76
Figure 3 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS) 76
Figure 3 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE) 77
Figure 3 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis 77
Figure 3 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA 78
Figure 3 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis 78
Figure 3 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis 79
Figure 3 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab) 79
Figure 3 27: Abatacept Post-marketing Clinical Study in Japan 80
Figure 3 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY) 80
Figure 3 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) 81
Figure 3 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE) 81
Figure 3 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) 82
Figure 3 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis 82
Figure 3 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis 83
Figure 3 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis 83
Figure 3 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. 84
Figure 3 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis 84
Figure 3 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT) 85
Figure 3 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI) 85
Figure 3 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs 86
Figure 3 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study 86
Figure 3 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H) 87
Figure 3 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent 87
Figure 3 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants 88
Figure 3 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC) 88
Figure 3 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT) 89
Figure 3 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects 89
Figure 3 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C) 90
Figure 3 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR) 90
Figure 3 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02) 91
Figure 3 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis 91
Figure 3 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis 92
Figure 3 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors 92
Figure 3 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY) 93
Figure 3 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis 93
Figure 3 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) 94
Figure 3 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate 94
Figure 3 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 95
Figure 3 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease 95
Figure 3 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA) 96Figure 3 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM) 96
Figure 3 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) 97
Figure 3 62: Adalimumab-psoriasis and Small Bowel Lesions 97
Figure 3 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas 98
Figure 3 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease 98
Figure 3 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) 99
Figure 3 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease 99
Figure 3 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA) 100
Figure 3 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis 101
Figure 3 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis 101
Figure 3 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis 102
Figure 3 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS) 102
Figure 3 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY) 103
Figure 3 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD) 103
Figure 3 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) 104
Figure 3 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis 104
Figure 3 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis 105
Figure 3 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA® 105
Figure 3 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR) 106
Figure 3 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim) 106
Figure 3 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO) 107
Figure 3 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE) 107
Figure 3 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE) 108
Figure 3 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE) 108
Figure 3 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE) 109
Figure 3 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN) 109Figure 3 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E) 110
Figure 3 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis 110
Figure 3 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS) 111
Figure 3 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE) 111
Figure 3 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis 112
Figure 3 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME) 112
Figure 3 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A 113
Figure 3 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) 113
Figure 3 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE) 114
Figure 3 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis 114Figure 3 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA) 115
Figure 3 97: Adalimumab-psoriasis and Small Bowel Lesions 115
Figure 3 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND) 116Figure 3 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) 116
Figure 3 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS) 117
Figure 3 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis 117
Figure 3 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis 118
Figure 3 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3) 118
Figure 3 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE) 119
Figure 3 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS) 119
Figure 3 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) 120
Figure 3 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis 120
Figure 3 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP) 121
Figure 3 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART) 122
Figure 3 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients 122Figure 3 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE) 123
Figure 3 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE) 123
Figure 3 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda) 124
Figure 3 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis 124
Figure 4 1: Immunology Market by Segment, U.S., 2014 - 2024 (US$M) (1 of 2) 127
Figure 4 2: Immunology Market by Segment, U.S., 2014 - 2024 (US$M) (2 of 2) 128
Figure 4 4: Immunology Market Share Analysis by Segment, U.S., 2014 - 2024 (1 of 2) 131
Figure 4 5: Immunology Market Share Analysis by Segment, U.S., 2014 - 2024 (2 of 2) 132
Figure 4 6: Rheumatoid Arthritis Prevalence Statistics, by Age and Gender, U.S., 2014 134
Figure 4 7: Patent Expiries of Marketed Drugs in Immunology 136
Figure 4 8: Drivers and Limiters, Immunology Market, U.S., 2017 139
Figure 4 9: Leading Competitors, Immunology Market, U.S., 2017 140
Figure 5 1: Prevalence of the immunology diseases in the U.S., 2017 143
Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017 144
Figure 5 3: Treatment Population Size of Crohn's Disease, U.S., 2017 144
Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017 144
Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017 145
Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017 145
Figure 5 7: List of U.S. Retail Pharmacies 146
Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2) 147
Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2) 147
Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S. 148
Figure 6 1: Rheumatoid Arthritis Market by Segment, U.S., 2014 - 2024 (US$M) (1 of 2) 155
Figure 6 2: Rheumatoid Arthritis Market by Segment, U.S., 2014 - 2024 (US$M) (2 of 2) 155
Figure 6 3: Rheumatoid Arthritis Market Growth by Segment, U.S., 2014 - 2024 (1 of 2) 158
Figure 6 4: Rheumatoid Arthritis Market Growth by Segment, U.S., 2014 - 2024 (2 of 2) 158
Figure 6 5: Leading Competitors, Rheumatoid Arthritis Market, U.S., 2017 160
Figure 7 1: Crohn's Disease Market by Segment, U.S., 2014 - 2024 (US$M) (1 of 2) 167
Figure 7 2: Crohn's Disease Market by Segment, U.S., 2014 - 2024 (US$M) (2 of 2) 167
Figure 7 3: Crohn's Disease Market Growth by Segment, U.S., 2014 - 2024 (1 of 2) 170
Figure 7 4: Crohn's Disease Market Growth by Segment, U.S., 2014 - 2024 (2 of 2) 170
Figure 7 5: Leading Competitors, Crohn's Disease Market, U.S., 2017 172
Figure 8 1: Ankylosing Spondylitis Market by Segment, U.S., 2014 - 2024 (US$M) 178
Figure 8 2: Ankylosing Spondylitis Market Growth by Segment, U.S., 2014 - 2024 (1 of 2) 181
Figure 8 3: Leading Competitors, Ankylosing Spondylitis Market, U.S., 2017 183
Figure 9 1: Psoriasis Market by Segment, U.S., 2014 - 2024 (US$M) 191
Figure 9 2: Psoriasis Market Growth by Segment, U.S., 2014 - 2024 (1 of 2) 194
Figure 9 3: Leading Competitors, Psoriasis Market, U.S., 2017 196
Figure 10 1: Ulcerative Colitis Market by Segment, U.S., 2014 - 2024 (US$M) 202
Figure 10 2: Ulcerative Colitis Market Growth by Segment, U.S., 2014 - 2024 (1 of 2) 205
Figure 10 3: Leading Competitors, Ulcerative Colitis Market, U.S., 2017 207
Figure 11 1: Key Facts, AbbVie Inc., 2017 209
Figure 11 2: Financials, AbbVie Inc., 2017 211
Figure 11 3: SWOT Analysis, AbbVie Inc., 2017 212
Figure 11 4: Key Facts, Amgen, 2017 216
Figure 11 5: Financial Overview, Amgen, 2017 217
Figure 11 6: SWOT Analysis, Amgen, 2017 218
Figure 11 7: Patent Expiries, Enbrel® 219
Figure 11 8: Key Facts, Biogen Idec 223
Figure 11 9: Financials, Biogen Idec, 2017 224
Figure 11 10: SWOT Analysis, Biogen Idec 225
Figure 11 11: Key Facts, Bristol-Myers Squibb 229
Figure 11 12: Financials, Bristol-Myers Squibb, 2017 230
Figure 11 13: Bristol-Myers Squibb, Key Products Revenue (US$M) 231
Figure 11 14: SWOT Analysis, Bristol-Myers Squibb 232
Figure 11 15: Key Facts, Hoffman-La Roche Ltd 237
Figure 11 16: Financials, Hoffman-La Roche Ltd , 2017 238
Figure 11 17: SWOT Analysis, Hoffman-La Roche Ltd 239Figure 11 18: Key Facts, Johnson & Johnson 243
Figure 11 19: Financials, Johnson & Johnson, 2017 244
Figure 11 20: SWOT Analysis, Johnson & Johnson 245
Figure 11 21: Key Facts, Novartis AG 250
Figure 11 22: Financials, Novartis AG, 2017 251
Figure 11 23: SWOT Analysis, Novartis AG 252
Figure 11 24: Key Facts, Pfizer Inc. 256
Figure 11 25: Financials, Pfizer Inc., 2017 257
Figure 11 26: SWOT Analysis, Pfizer Inc. 258
Figure 11 27: Key Facts, Takeda Pharmaceutical Company Limited 263
Figure 11 28: Financials, Takeda Pharmaceutical Company Limited , 2017 264
Figure 11 29: SWOT Analysis, Takeda Pharmaceutical Company Limited 265
Figure 11 30: Key Facts, UCB S.A. 270
Figure 11 31: Financials, UCB S.A., 2017 271
Figure 11 32: SWOT Analysis, UCB S.A. 272
Figure 13 1: Press Release Summary 278

Companies
• The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases. The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.